GRN and Parkinson disease: Individuals with GRN mutations and Parkinsonism could show reduced DOPA metabolism in bilateral corpus striatum by 18F-DOPA PET (59) or reduced tracer uptake in left putamen by 123I-ioflupane SPECT (61).